Genetic Basis And Pathophysiology

  • Spinal Muscular Atrophy (SMA) is an autosomal recessive neuromuscular disease caused by homozygous deletions or mutations in the SMN1 gene on chromosome 5q13.
  • Loss of SMN1 leads to deficiency of Survival Motor Neuron (SMN) protein, causing progressive degeneration of anterior horn alpha motor neurons, severe symmetrical flaccid paralysis, and respiratory failure.
  • Humans possess a nearly identical centromeric paralog, SMN2, which differs by a single nucleotide ($C\rightarrow T$ transition at position 6 of exon 7).
  • This transition alters alternative splicing such that approximately 85% to 90% of SMN2 transcripts lack exon 7 ($\text{SMN}\Delta 7$), producing an unstable, rapidly degraded protein, while only 10% to 15% yields functional full-length SMN protein.
  • SMN2 copy number inversely correlates with clinical severity: SMA Type 1 typically has 2 copies, Type 2 has 3 copies, and Type 3 has 3 to 4 copies.

Approved Disease-Modifying Therapies (DMTs)

Three disease-modifying therapies are approved that either replace the deficient gene or modify SMN2 pre-mRNA splicing to enhance functional SMN protein production.

1. Onasemnogene Abeparvovec (Zolgensma)

  • Recombinant adeno-associated virus serotype 9 (AAV9) gene replacement therapy.
  • Delivers a functional copy of the human SMN1 cDNA driven by a hybrid CMV/chicken $\beta$-actin promoter.
  • Administered as a single-dose intravenous infusion ($1.1 \times 10^{14}\text{ vector genomes/kg}$) over 60 minutes for children aged <2 years.
  • Pre-treatment screening mandates testing for anti-AAV9 antibody titers (must be $\le 1:50$ to avoid vector neutralization).
  • Requires oral prednisolone (1 mg/kg/day) starting 24 hours prior to infusion and continued for at least 30 days to mitigate capsid-mediated hepatotoxicity.
  • Boxed warnings include acute liver failure, thrombotic microangiopathy (TMA), and troponin-I elevation (myocardial toxicity).
  • Intrathecal formulation (OAV-101 / Itvisma) has demonstrated motor gains in older children in the STEER Phase 3 trial.

2. Nusinersen (Spinraza)

  • Chemically modified 2'-O-(2-methoxyethyl) antisense oligonucleotide (ASO).
  • Binds to an intronic splice silencer (ISS-N1) in intron 7 of the SMN2 pre-mRNA, displacing negative splicing factors and forcing exon 7 inclusion to generate full-length SMN protein.
  • Does not cross the blood-brain barrier; administered strictly via intrathecal lumbar puncture.
  • Dosing schedule: 12 mg (5 mL) loading doses at Day 0, Day 14, Day 28, and Day 63, followed by maintenance doses every 4 months indefinitely.
  • Landmark trials: ENDEAR (infantile-onset, showed 51% motor milestone achievement vs 0% sham) and CHERISH (later-onset).
  • Safety monitoring: Baseline platelet count, coagulation profile, and urine protein (risk of thrombocytopenia and renal glomerulonephritis).

3. Risdiplam (Evrysdi)

  • Orally administered small-molecule SMN2 pre-mRNA splicing modifier with broad systemic tissue distribution.
  • Enhances exon 7 inclusion in SMN2 transcripts systemically in both central and peripheral tissues.
  • Administered once daily as an oral liquid solution after a meal.
  • Dosing:
    • Age <2 months: 0.15 mg/kg/day.
    • Age 2 months to <2 years: 0.20 mg/kg/day.
    • Age $\ge 2$ years weighing <20 kg: 0.25 mg/kg/day.
    • Age $\ge 2$ years weighing $\ge 20$ kg: 5 mg/day (fixed maximum dose).
  • Landmark trials: FIREFISH (Type 1 infants; achieved ventilator-free survival and independent sitting) and SUNFISH (Types 2 and 3).
  • Avoids lumbar punctures, facilitating treatment in children with severe scoliosis or spinal instrumentation.

Comparison Of The Three Approved DMTs

ParameterOnasemnogene AbeparvovecNusinersenRisdiplam
MechanismSMN1 gene replacement via AAV9Intrathecal ASO SMN2 splice modifierOral small molecule SMN2 splice modifier
Route Of DeliverySingle-dose IV infusionIntrathecal lumbar punctureDaily oral solution
DistributionPrimarily CNS and liverConfined to CNS / spinal cordSystemic (CNS and peripheral organs)
Administration ScheduleOnce in a lifetimeLoading (4 doses) then every 4 monthsDaily lifelong oral dosing
Key MonitoringLiver function, platelets, troponin, TMAPlatelets, renal function (proteinuria)Ophthalmic screening, hepatic enzymes
Major AdvantageOne-time permanent cure potentialExtensive long-term safety dataNon-invasive oral route; avoids LP

Newborn Screening (NBS) In SMA

  • SMA satisfies all Wilson and Jungner criteria for newborn screening: presymptomatic phase, definitive screening test, and effective treatment.
  • Screening utilizes real-time PCR or digital droplet PCR on dried blood spot (DBS) cards to detect homozygous deletion of SMN1 exon 7.
  • Secondary reflex testing quantifies SMN2 copy number to triage urgency of therapy.
  • The NURTURE trial (nusinersen) and SPR1NT trial (onasemnogene) demonstrated that treating infants in the presymptomatic phase achieves near-normal motor milestones:
    • 100% of infants with 2 or 3 SMN2 copies survived without permanent ventilation.
    • Over 75% to 90% achieved independent walking within the normal developmental age window.
  • Motor neurons degenerate irreversibly once symptoms appear; presymptomatic therapy preserves native motor units.

India Access And Regulatory Framework

  • SMA is classified under Group 3 (disorders requiring high-cost lifelong therapy) in the National Policy for Rare Diseases (NPRD 2021/2025).
  • Financial assistance up to ₹50 lakh is provided per eligible patient through designated Centres of Excellence (CoE) via the Rashtriya Arogya Nidhi portal.
  • The Government of India has granted complete exemption from basic customs duty and GST on the import of personal-use SMA medicines (such as Zolgensma and Spinraza).
  • Humanitarian access includes the Novartis Global Managed Access Program (lottery-based compassionate allocation for onasemnogene) and Roche's patient co-pay and compassionate access schemes for risdiplam.